VBLT Vascular Biogenics Ltd

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

 

For the month of October 2020

 

Commission File Number: 001-36581

 

 

Vascular Biogenics Ltd.

(Translation of registrant’s name into English)

 

 

8 HaSatat St.,

Modi’in,

Israel 7178106

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F [X]             Form 40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes [  ]             No [X]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes [  ]            No [X]

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]            No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

 

 

 

EXPLANATORY NOTE

 

On October 19, 2020, Vascular Biogenics Ltd. (the “Company”) announced an extraordinary general meeting of shareholders (the “Meeting”) and made available to its shareholders certain other materials in connection with such meeting.

 

Furnished herewith as Exhibits 99.1 and 99.2, respectively, are the following documents relating to the Meeting:

 

1.	Notice of the Extraordinary General Meeting of Shareholders to be held on November 24, 2020.
2.	Proxy Statement and Proxy Card for use in connection with the Meeting.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	VASCULAR BIOGENICS LTD.
Date: October 19, 2020	By:	/s/ Dror Harats
	Name:	Dror Harats
	Title:	Chief Executive Officer

 

3

 

 

EXHIBIT INDEX

 

The following exhibits are furnished as part of this Form 6-K:

 

Exhibit
99.1		Notice of Extraordinary General Meeting of Shareholders to be held on November 24, 2020
99.2		Proxy Statement and Proxy Card for use in connection with the Meeting.

 

4